Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: A prospective cohort study from the international T-cell Project Journal Article


Authors: Fox, C. P.; Civallero, M.; Ko, Y. H.; Manni, M.; Skrypets, T.; Pileri, S.; Kim, S. J.; Cabrera, M. E.; Shustov, A. R.; Chiattone, C. S.; Horwitz, S. M.; Dlouhy, I.; Spina, M.; Hitz, F.; Montoto, S.; Nagler, A.; Martinez, V.; De Souza, C. A.; Fernandez-Alvarez, R.; Ballova, V.; Gabús, R.; Inghirami, G.; Federico, M.; Kim, W. S.
Article Title: Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: A prospective cohort study from the international T-cell Project
Abstract: Background: Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological entity, typically associated with poor survival outcomes. Most published data have come from east Asian study groups, with little information available from international cohorts. The effects of treatment advances on routine clinical practice across continental territories has not been clear. We aimed to improve understanding of the clinical characteristics and outcomes of patients with ENKTL. Methods: We did a substudy of patients with ENKTL from the T-cell Project, a global prospective cohort study. The T-cell Project registered consecutively diagnosed adults (>18 years) with newly diagnosed, untreated mature T-cell or NK lymphomas (WHO 2001 or 2008 classifications) from 74 centres in 13 countries (in Asia, Europe, North America, and South America). In total, 1695 patients with mature T-cell or NK lymphomas were enrolled between Oct 12, 2006 and Feb 28, 2018 in the T-cell Project. The first patient with ENKTL was enrolled on Feb 15, 2007, and the last on May 26, 2017. Data on baseline characteristics, first-line treatment, treatment response, and survival outcomes were recorded in a central database (locked March 30, 2019). The primary outcome was 5-year overall survival. The T-cell Project is registered on ClinicalTrials.gov, NCT01142674. Findings: 166 patients were diagnosed with ENKTL, comprising 11% of 1553 eligible registered cases and distributed across 40 participating centres in four continents. At a median follow-up of 44 months (IQR 20–61), overall survival at 5 years was 54% (95% CI 44–63) in patients with nasal disease (n=98) and 34% (27–46) in patients with extranasal disease (n=68). Interpretation: To our knowledge, this study presents the largest international cohort of patients with ENKTL. We describe a clinically significant improvement in the survival of patients with ENKTL treated in routine clinical practice over the past decade, likely to be attributable to the increasing use of treatment protocols specific for ENKTL. Funding: The Fondazione Cassa di Risparmio di Modena, the Associazione Angela Serra per la Ricerca sul Cancro, the Fondazione Italiana Linfomi, Allos Therapeutics, Spectrum Pharmaceuticals, Associazione Italiana per la Ricerca sul Cancro, and the National Cancer Institute at the National Institutes of Health. © 2020 Elsevier Ltd
Keywords: adult; cancer survival; controlled study; treatment outcome; treatment response; aged; survival analysis; major clinical study; overall survival; clinical trial; cisplatin; gemcitabine; disease free survival; methotrexate; outcome assessment; follow up; prospective study; cancer immunotherapy; progression free survival; etoposide; cohort analysis; dexamethasone; retrospective study; cancer research; ifosfamide; cause of death; death; multicenter study; asparaginase; platinum; lactate dehydrogenase; anthracycline; nk t cell lymphoma; recurrence free survival; international prognostic index; clinical outcome; cancer prognosis; brentuximab vedotin; human; male; female; priority journal; article
Journal Title: The Lancet Haematology
Volume: 7
Issue: 4
ISSN: 2352-3026
Publisher: Elsevier Science, Inc.  
Date Published: 2020-04-01
Start Page: e284
End Page: e294
Language: English
DOI: 10.1016/s2352-3026(19)30283-2
PUBMED: 32105608
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 April 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Steven M Horwitz
    668 Horwitz